ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT07232043
- Status
- Recruiting
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MatchMiner-AI Artificial Intelligence Tool — OTHEROncologists receive email notifications containing a ranked list of potential clinical trial options when AI models detect progressive disease, in addition to standard MatchMiner-AI access.
Study Details
This study aims to develop and evaluate ACTIVATE, an AI-driven tool for clinical trial information and viability assessment using electronic health records (EHRs). The project will leverage retrospective and prospective EHR data to build and validate algorithms that identify potentially eligible participants for clinical trials and facilitate trial matching.
Key Dates
- First listed
- Nov 18, 2025
- Start date
- Jul 20, 2026
- Status verified
- Sep 2026
- Primary completion
- Jun 30, 2030
- Completion
- Jun 30, 2030
Study Design
- Enrollment
- 70,000 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- No Intervention: Standard MatchMiner-AI WorkflowOncologists can access the MatchMiner-AI frontend website to obtain a list of clinical trial options for all participants.
- Experimental: Proactive AI-Triggered NotificationsOncologists receive email notifications containing a ranked list of potential clinical trial options when AI models detect progressive disease, in addition to standard MatchMiner-AI access.
Primary Outcome Measure
Proportion clinical trials [ Time Frame: Assessment will occur at the end of the 1.5 year duration of the intervention. ]
Central Contacts
- Kenneth L Kehl, MD617-632-4550
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Kenneth Kehl, MD, MPH (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Boston, MA
By research site
Related Studies
- Evaluation of Non-Invasive Assays for the Detection of Urothelial CancerRecruiting · Lahey Clinic · Burlington, Massachusetts
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6PHASE2 · Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama